Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 9,787	$ 9,981
Available-for-sale investments	92,344	56,165
Other receivables	2,087	11,775
Prepaid expenses	3,080	2,950
Total current assets	107,298	80,871
Restricted cash	3,451	3,165
Property and equipment, net	5,644	3,059
Operating lease, right-of-use assets	6,812	7,250
Financing lease, right-of-use assets	1,791	1,248
Other assets	73	193
Total assets	125,069	95,786
Current liabilities:
Accounts payable	2,043	3,106
Accrued expenses	9,605	9,862
Current portion of operating lease liability	774	630
Current portion of financing lease liability	459	264
Total current liabilities	12,881	13,862
Long-term operating lease liability, net of current portion	12,548	9,633
Long-term financing lease liability, net of current portion	1,437	1,007
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $0.001 par value per share; 5,000,000 undesignated authorized shares as of September 30, 2023 (unaudited) and December 31, 2022; no shares issued or outstanding as of September 30, 2023 (unaudited) and December 31, 2022
Common stock, $0.001 par value per share; 170,000,000 and 85,000,000 authorized shares as of September 30, 2023 (unaudited) and December 31, 2022, respectively; issued and outstanding shares-58,560,061 as of September 30, 2023 (unaudited) and 29,498,488 as of December 31, 2022	59	29
Additional paid-in capital	551,888	489,502
Accumulated other comprehensive loss	(294)	(433)
Accumulated deficit	(453,263)	(417,634)
Total aTyr Pharma, Inc. stockholders’ equity	98,390	71,464
Noncontrolling interest in Pangu BioPharma Limited	(187)	(180)
Total stockholders’ equity	98,203	71,284
Total liabilities and stockholders’ equity	$ 125,069	$ 95,786